Detalhe da pesquisa
1.
A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.
Oncologist
; 29(1): e131-e140, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531083
2.
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
Clin Cancer Res
; 25(17): 5202-5211, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142504